Microbiología y Parasitología
Departamento
FRANCISCO
BOLAS FERNÁNDEZ
Investigador hasta 2022
Publicaciones en las que colabora con FRANCISCO BOLAS FERNÁNDEZ (101)
2023
-
Can amphotericin B and itraconazole be co-delivered orally? Tailoring oral fixed-dose combination coated granules for systemic mycoses
European Journal of Pharmaceutics and Biopharmaceutics, Vol. 183, pp. 74-91
-
Targeting lung macrophages for fungal and parasitic pulmonary infections with innovative amphotericin B dry powder inhalers
International journal of pharmaceutics, Vol. 635, pp. 122788
2022
-
Lentinula edodes extract increases goblet cell number and Muc2 expression in an intestinal inflammatory model of Trichinella spiralis infection
Biomedicine and Pharmacotherapy, Vol. 150
-
Self-assembling, supramolecular chemistry and pharmacology of amphotericin B: Poly-aggregates, oligomers and monomers
Journal of Controlled Release, Vol. 341, pp. 716-732
2020
-
(E)-piplartine isolated from piper pseudoarboreum, a lead compound against leishmaniasis
Foods, Vol. 9, Núm. 9
-
Evaluating the potential of ursolic acid as bioproduct for cutaneous and visceral leishmaniasis
Molecules, Vol. 25, Núm. 6
-
Nucleotides and AHCC Enhance Th1 Responses in Vitro in Leishmania-Stimulated/Infected Murine Cells
Molecules, Vol. 25, Núm. 17
-
Oral Fixed-Dose Combination Pharmaceutical Products: Industrial Manufacturing Versus Personalized 3D Printing
Pharmaceutical Research, Vol. 37, Núm. 7
-
Topical buparvaquone nano-enabled hydrogels for cutaneous leishmaniasis
International Journal of Pharmaceutics, Vol. 588
-
Transferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scale
International Journal of Pharmaceutics, Vol. 573
-
Ultradeformable Lipid Vesicles Localize Amphotericin B in the Dermis for the Treatment of Infectious Skin Diseases
ACS Infectious Diseases, Vol. 6, Núm. 10, pp. 2647-2660
2019
-
Repurposing butenafine as an oral nanomedicine for visceral leishmaniasis
Pharmaceutics, Vol. 11, Núm. 7
2018
-
In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species
Experimental Parasitology, Vol. 184, pp. 82-89
-
Intraperitoneal administration of the anti-IL-23 antibody prevents the establishment of intestinal nematodes in mice
Scientific Reports, Vol. 8, Núm. 1
-
Optimising the in vitro and in vivo performance of oral cocrystal formulations via spray coating
European Journal of Pharmaceutics and Biopharmaceutics, Vol. 124, pp. 13-27
-
Orally Bioavailable and Effective Buparvaquone Lipid-Based Nanomedicines for Visceral Leishmaniasis
Molecular Pharmaceutics, Vol. 15, Núm. 7, pp. 2570-2583
-
Systematic search for benzimidazole compounds and derivatives with antileishmanial effects
Molecular Diversity, Vol. 22, Núm. 4, pp. 779-790
2017
-
A novel LAMP assay for Trichuris spp. detection in stool and urine samples from a rodent model
XX Congreso de la Sociedad Española de Parasitología (SOCEPA)
-
Engineering oral and parenteral amorphous amphotericin B formulations against experimental Trypanosoma cruzi infections
Molecular Pharmaceutics, Vol. 14, Núm. 4, pp. 1095-1106
-
Leishmaniasis in the major endemic region of Plurinational State of Bolivia: Species identification, phylogeography and drug susceptibility implications
Acta Tropica, Vol. 176, pp. 150-161